MedTrace Logo

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

NCT02043301 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-05-31

Study results available
· View outcomes & findings →

Summary

This study aims to characterize the single dose pharmacokinetics of PF-04950616 following subcutaneous injection to the abdomen, upper arm or the thigh.

Conditions

Interventions

BIOLOGICAL

Bococizumab (PF-04950615; RN316)

Single 150 mg PF-04950615 dose administered SC to the abdomen

BIOLOGICAL

Bococizumab (PF-04950615; RN316)

Single 150 mg PF-04950615 dose administered SC to the upper arm

BIOLOGICAL

Bococizumab (PF-04950615; RN316)

Single 150 mg PF-04950615 dose administered SC to the thigh

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02043301 on ClinicalTrials.gov